Humana (NYSE:HUM) Releases FY 2025 Earnings Guidance

Humana (NYSE:HUM) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 16.250-16.250 for the period, compared to the consensus earnings per share estimate of 16.410. The company issued revenue guidance of -.

Humana Price Performance

NYSE:HUM opened at $265.20 on Thursday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a fifty day simple moving average of $268.97 and a 200 day simple moving average of $272.62. Humana has a 1-year low of $213.31 and a 1-year high of $406.46. The stock has a market capitalization of $32.01 billion, a PE ratio of 26.65, a P/E/G ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, research analysts expect that Humana will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.33%. Humana’s payout ratio is currently 35.58%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. StockNews.com cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, March 18th. Royal Bank of Canada restated an “outperform” rating and issued a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. JPMorgan Chase & Co. lowered their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Barclays raised their target price on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. Finally, Truist Financial lifted their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Eighteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Humana presently has a consensus rating of “Hold” and an average target price of $285.68.

Institutional Trading of Humana

An institutional investor recently bought a new position in Humana stock. Revolve Wealth Partners LLC purchased a new stake in Humana Inc. (NYSE:HUM) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 798 shares of the insurance provider’s stock, valued at approximately $202,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.